Since the beginning of this year, Hoyotek Biomedical co., LTD. has made frequent reports of good news: the blood early screening and diagnosis reagent for Alzheimer's disease independent researched and developed by the Company has been officially launched in May, and has been marketed and used for routine testing in major tertiary and secondary hospitals and clinical inspection centers in Guizhou, Chengdu, Chongqing, Gansu, Shaanxi and other regions. From May to July, the Company has won 51 EU CE certificates, 30 NMPA certificates and two invention patents. Up to present, Hoyotek has been granted more than 180 CE certificates, more than 70 NMPA certificates, 3 invention patents and 23 utility model patents.

Hoyotek has newly been granted 51 EU CE certificates, including 26 for luminescent kits, 3 for fluorescent kits, and 22 for quality control items corresponding to luminescent kits, which mainly involve the detection of thyroid function, the detection of human reproductive hormone, the detection of tumor markers, as well as the detection of anemia related ferritin. The two invention patents are respectively titled as "A serum-free medium and its application, a construction method of recombinant antibody expressed by CHO cells" and "An extraction method of periplasmic protein from Escherichia coli cells".

Nowadays, Hoyotek, established in Tianjin Port Free Trade Zone in August 2020, has become a high and new technology enterprise in Tianjin integrating the innovative R&D, production and marketing of the overall industrial chain, focusing on the development and production of diagnostic reagents in the fields of POCT, magnetic particle chemiluminescence and molecular diagnostics. Hoyotek has its own raw material R&D platform, and has made remarkable achievements in the research and development of Alzheimer's disease related fields by using unique innovative technologies.

The blood early screening and diagnostic reagent for Alzheimer's disease developed by the Company has been officially launched into the market in May this year, which can satisfy the different demands of hospitals at all levels such as township health centers, community clinics, physical examination institutions, and tertiary hospitals, and is of great significance for the early screening of elderly patients with dementia. The series of products are applicable for chemiluminescence and POCT platforms. For the two technical platforms, Hoyotek has independently designed and developed raw materials, innovates reagent formula and process, and established antigen-antibody expression platform and luminous magnetic bead development technology platform with independent intellectual property rights, thereby solving the problem of technical barriers and price monopoly of foreign manufacturers. Hoyotek has also engaged in developing blood early screening and diagnosis of Alzheimer's disease, and more related products will be launched at the later stage.

The biomedical industry is one of the strategic emerging industries in Tianjin. Over the years, the Free Trade Zone has always been committed to promoting scientific and technological innovation and industrial development, and vigorously promoting the biomedical industry. In the future, the Tianjin Port Free Trade Zone will continue to implement the concept of "Party Building Leading and Joint Construction", reinforce the solid support of high-quality development, promote the integration of innovative elements, further expedite the implementation of the innovation-driven development strategy, gather forces in original and pioneering scientific and technological research, enhance the ability of independent innovation, spare no efforts in promoting high-quality development of the pharmaceutical industry, so as to make the due contribution of the Free Trade Zone in the construction of the Tianjin City and Binhai New Area.